Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/8C14ACF9.svg?ark=w1%2F20260515%2F8C14ACF9)](https://nobleid.org/work/w1/20260515/8C14ACF9)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors